Virtus ETF Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Virtus ETF Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,381	Closed	-$854K	–	474
2023 Q3	$854K	Buy	7,381 +460	+7%	+$49.4K	0.52%	12
2023 Q2	$712K	Sell	6,921 -946	-12%	-$99.8K	0.42%	107
2023 Q1	$859K	Buy	+7,867	New	+$870K	0.47%	74
2022 Q4	–	Sell	-8,094	Closed	-$501K	–	489
2022 Q3	$501K	Buy	+8,094	New	+$566K	0.2%	211

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Virtus ETF Advisers's HZNP Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,381 shares — an estimated $854K sold.

Virtus ETF Advisers first reported a position in HZNP in Q3 2022 and held it in 4 quarters. The position peaked at $859K in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Virtus ETF Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Virtus ETF Advisers sold 7,381 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $854K.
Virtus ETF Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022 and held it in 4 quarters.
Virtus ETF Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $859K in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.